RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

Abstract Background The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown. We determined th...

Full description

Bibliographic Details
Main Authors: Ruomei Xu, Parveen Fathima, Tobias Strunk, Nicholas de Klerk, Thomas L. Snelling, Peter C. Richmond, Anthony D. Keil, Hannah C. Moore
Format: Article
Language:English
Published: BMC 2020-10-01
Series:BMC Pediatrics
Subjects:
Respiratory syncytial virus
Palivizumab
Infants
Neonatal intensive care unit
High-risk
Online Access:http://link.springer.com/article/10.1186/s12887-020-02390-5

Internet

http://link.springer.com/article/10.1186/s12887-020-02390-5

Similar Items